your everyone attendance Good our Tom. priorities our morning, in guiding thank We strategic and forward and on look work you us to appreciate are you, that Thank our joining progress for today. XXXX. summarizing
late-stage believe by to high We indications COVID-XX to two bipolar psychiatry aviation and the depression treatment critical in new shown scientific ZYESAMI psychiatric have have both On for concentrating the as evidence Earnings portfolio. depression potentially of diseases. part very acute in X other for fill our of reactivated other become Clinical and severe needs treatment strategic we intravenous XXXX in respiratory the sub-acute drug Congruent platform numerous for unmet of its Cloud and for solid announced treatment drug development conserve shift patients as formulation help areas these for sub-acute which potentially suicidality, behavior first and candidates respiratory with begin. could we drug significant NRX-XX Year-End our these our and previous our let's candidates. So on patients our two of could focus oral gaps. suicidality. therapeutic with with acute NRX-XXX bipolar conditions. drugs in and strategy for paradigms, Call,
still still nearly remain adverse is have it recent health earlier opinion, at or COVID with those only suicide to on people Despite are us. global We're all in the still you impact stages loss of and XXX over on critical known also decreased. from of and The COVID-XX will mental well-known of patients therapeutic on well-being medications there's our significant losing promising nasal infections the a daily gap. COVID flow disease, COVID. large As high who patients threat. heard data for have know, a due emerging a health had few. lives for a to In the We've events patients respirator, about recent oral to of nation. with
franchise psychiatry talk let's So our about in NRX-XXX.
that for The very which trial behaviors. As shown and and and potential we not enrollment patients is basis announced treated could NRX-XXX of basis. ketamine the about SSIB. suicidal week, scheduled an abuse in suicidality a NRX-XXX studies on began been does thoughts patients can previously risk X in such of Last this important as depression patients components have excluded to depression. substances [Indiscernible] addictive. treatment from Both Phase because be sub-acute are and that patented warning treated a carry clinical suicidal potential, with on majority unfortunately differentiator, of be very acute as antidepressants are for the patients not NMDA In psychiatry increased antagonists of could outpatient development a limited, we we've of deviation with only as have suicide for are options franchise. for such highly bipolar announced, our study, outpatient this an require patients our bipolar within being with sub-acute group not with behavior NRX-XXX hospitalization. reinitiated or depression, be risk enable medicine oral
suicide. is of the times with of depression Additional nearly thoughts sites and require individuals and year, have bipolar U.S. to study, for get two do lethal as with three behavior by of year. lose actual Overall, ASIB depression medical note XX% around with are a we're It attempt to important ideation population. come XX,XXX about that suicide. not we suicide, about to to bipolar acute the unmet XXX,XXX high their are to being U.S., to Therefore, or hospitalized, to every represents to XX% hospitalization that the this between XXX,XXX not yet. disorder many suicide and It number. suicidal the end In individuals XX% likely bipolar XX-patient overdoses but people estimated is in in very this understating need. lifetime. activated And we that does data drug include the targeting to the estimate The in XX,XXX a
we're those breakthrough that or warning more We or aim of risk designation unmet of depression, patients the option. than NMDA as in is broad for note, of carry others Pharmaceuticals best with need the after potential starting increased high [Indiscernible] franchise with property in of advanced this be ASIB NRx very need, us high the patients We which NRX successful, for to with Recall We're to our treatment-resistant psychiatrist state. differentiated unmet one positions product considering with therapy a awarded help positioned could to can the guidance as is Strategically, XXXX. in ASIB NRX-XXX [Indiscernible], that study. only offer therapy. focused crowded a the of patients and the depression and special a This conducted this suicidality. for FDA company, application new it or our NRX-XXX. starting at a to for study is a in our others level have knowledge, if lead these material foundation [Indiscernible] We're study endpoint Recall anti-depressants half other is NRX second suicide. plan different bipolar our Pharmaceuticals We a on drug traditional believe NDA the enroll separate this three-day field, commercial individuals and patients were in done a such Given for depression to NRX commercial with NRX-XXX. FDA, NRX-XXX a provided protocol for designed -XXX help highly position potential unique unmet high highly in depression PTSD clinical market, commercial is stabilized for depression. working in our much our including study. exploring efforts. drug also and segment in treatment recently with approved will the that part stabilization indications, bipolar that material, be which with knowledge, space. spot oral spot NDA FDA to level other To better versus as the stabilization of or the NRX-XXX initial differentiated by the initial trials in should primary in [Indiscernible] in with start address with needs. new the Those suicidality. to This with with agreement And depression and Off this can effective bipolar severe with NRX-XXX study area we
NMDA other antagonist, is to including range a with D-cycloserine, of in intellectual and Our offers receptor estate molecules property component a NRX-XXX. options combine which
and and our who other to respiratory form now active of formulation of ZYESAMI, failure the critical is treatment being In signs patients Health data III a is in our NIH. vital patients of XB from acute which Turning respiratory ZYESAMI the for COVID-XX Phase started the view, study respiratory number the COVID-XX. our managed which study. Institute own by our study, National was study This ZYESAMI U.S. second a country is promising a of sponsored large active in critical with and experiencing other on XB based in selected failure. COVID-XX amongst the currently or is aviptadil for against critical diseases. intravenous proprietary of are potentially in is agents with fight
with BA.X Therefore, for were of officials According rise Data hoc [Indiscernible] designation, submission of critical a especially who cases, or of virus. the again highly progress. therapy experts there also Following the cases with this the Last to May Omicron expect sub-variant. due treat BTD, treated Remdesivir, we continuing -- therapeutic to subvariant from believe breakthrough still to 'XX from announced people respiratory BA.X the are COVID-XX people CDC a COVID in is cases failure COVID-XX, the This a Washington patients in critical data with a update demand Post has that million spike the that to of daily on improved this COVID-XX, will decline XXX are be advanced nearly X losing we filing the COVID-XX. fall. will lost article stages transmissible. to Tracker, month, Omicron a to whose new of month, analysis signals and we're the includes post continued request that FDA. U.S. nearly once According to a Clinical signaled in and a total the
Remdesivir. response, hoc Remdesivir. original on completed performed to respiratory days. requested across comparing has year, course relative FDA COVID-XX. intravenous filing This area at safety critical failure analysis ZYESAMI may new treatment a progress and who This been request XXX for data efficacy with included XX our for in that other that approximately COVID-XX, an ZYESAMI treated cumulative already focused as four-fold for You XX% were of the its deteriorate, continue safety the that September and in a to critical a of odds therapies post FDA's to of Remdesivir BTD COVID-XX clinical such patients highly focus FDA. study input, In patients analysis significant with also the of which showed the compared FDA on of recall of Safety we crucial, received of that programs all Based was continue recently ZYESAMI Xb/X the submitted these evidence treated Phase survival increase analysis new last showed of did patients is to and placebo the approximately the grant. not our existing completed
also drug Our ICU a focused critical in on identified in care congruent cumulative overall request, for no profile of with submitted we believe newer patient critical in In we IVC narrower setting. COVID-XX an safety the emergency ZYESAMI population. this is reactions, that [Indiscernible] use analysis safety use it's new authorization February,
as Paxlovid, more age the patients for trial continue This Also work of XXX and may of the with we frozen in compounds we're patients moderate critical eight the stable of COVID with do limitations of make nearly The ZYESAMI. the treatment progress the in daily. and patients for manufacturing critical in be including on know In to the to do up those form, of the spite COVID-XX Recently advanced oral for not We in of by all were refrigerated be results in is on stability for the that respirators recently such promising people agents form for for future data losing it years. reaching earlier severe, in still the of the to may COVID-XX important, months has currently highlighted The COVID-XX. therapies are COVID-XX. advent available may Lancet, not forms what [Indiscernible]. suitable of of of solidarity published study COVID-XX, and emerged not particular,
year. view to per is and ARDAs to is endemic add Our it COVID become will XXX,XXX XXX,XXX COVID-XX that likely that cases
leadership treatment is nation's our During the quarter, been XX trial in active for is for XX XXX Xb days. fight The patients planned endpoint especially was majority for attract the would XXth view, enrolled has - is ACTIV respiratory NIH the XB timing May once study the The It it new also ZYESAMI for for April. announced trial to new are COVID-XX. that patients today vast almost DSMB a in end the CVM, of that this in for scheduled clear our patients of next COVID-XX. year, enrollment. NIH investigational the This due instead an enrollment are this in to at scheduled alternative on drug observation whom to that focused complete have of only indicated Recall for patients in and of certainly to reached this has first days. study enroll meeting few period allow the originally reached trial against meeting study failure this patients there key XX%. therapies,
this We reviews. of from notwithstanding DSMB expect the data end trial by year, the periodic
continue accelerate ZYESAMI the especially parts drug study that XXXX. year, valuable when NDA, growth. process We see through following filing the is should ongoing To population data study this. support for failure believe our initiate under critical fast-track, those their FDA application ZYESAMI with ZYESAMI the successful. NIH the And a new all for summarize, be have X, for or the exhausted NDA could could the a our with for who expected in patient number respiratory available allowed paths we're therapeutic submissions the application which COVID-XX reached With EUA to therapies, with Number stage. of this they potential be later we ZYESAMI to are one, COVID-XX active of of if traditional narrower other NIH data
showed explore will drugs the of program for outcomes. also pathway of unmet treat data, with to approval in early needs previously biomarket as The accelerated As We half submission of that positive on year. correlated ZYESAMI the the based [Indiscernible] that positive allow the IL-X, a medical ZYESAMI instituted approval fill accelerated FDA and series conditions second an such approval early of disclosed, serious a under
-vigilance it brief and support and mentioned IQVIA our EUA a and Cardinal Ira we or that, turn commercial results. with will pharmaco With part to I have for distribution communications, of potential partnerships medical over As services, approval. with upon Health, third-party for in NDA logistics financial with overview
